TRVN Trevena Inc

Trevena Inc is a clinical stage biopharmaceutical company. It discovers, develops and commercialize therapeutics that use a novel approach to target G protein coupled receptors.

$0.16
As of 10/03/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/31/2014
Outstanding shares:  173,681,085
Average volume:  580,765
Market cap:   $26,851,096
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BGDW0N7
Valuation   (See tab for details)
PE ratio:   -0.46
PB ratio:   0.51
PS ratio:   45.74
Return on equity:   -89.47%
Net income %:   -7,529.12%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy